HighTower Advisors LLC Increases Position in Organon & Co. (NYSE:OGN)

HighTower Advisors LLC lifted its holdings in Organon & Co. (NYSE:OGN) by 0.5% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 163,440 shares of the company’s stock after buying an additional 855 shares during the period. HighTower Advisors LLC owned approximately 0.06% of Organon & Co. worth $2,439,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Organon & Co. by 14.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 63,269 shares of the company’s stock valued at $944,000 after purchasing an additional 7,763 shares during the last quarter. Kendall Capital Management lifted its stake in Organon & Co. by 3.6% in the fourth quarter. Kendall Capital Management now owns 57,545 shares of the company’s stock valued at $859,000 after purchasing an additional 2,025 shares during the last quarter. CM Management LLC lifted its stake in Organon & Co. by 50.0% in the fourth quarter. CM Management LLC now owns 150,000 shares of the company’s stock valued at $2,238,000 after purchasing an additional 50,000 shares during the last quarter. Amundi lifted its stake in Organon & Co. by 37.3% in the fourth quarter. Amundi now owns 616,390 shares of the company’s stock valued at $9,860,000 after purchasing an additional 167,553 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC purchased a new position in Organon & Co. in the fourth quarter valued at approximately $236,000. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on OGN. TD Cowen upgraded Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Barclays lowered their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Finally, Morgan Stanley lowered their target price on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $20.80.

Organon & Co. Stock Down 1.7 %

OGN opened at $15.33 on Friday. The stock has a market cap of $3.95 billion, a PE ratio of 4.60, a P/E/G ratio of 0.90 and a beta of 0.76. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. Organon & Co. has a 52 week low of $13.87 and a 52 week high of $23.10. The business’s fifty day simple moving average is $15.44 and its 200 day simple moving average is $16.45.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. As a group, research analysts expect that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were paid a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.31%. Organon & Co.’s dividend payout ratio is presently 33.63%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.